(S (ADVP (RB Herein)) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (JJ deep) (ADJP (NN learning) (HYPH -) (VBN based)) (NN approach)) (PP (IN for) (NP (NP (DT the) (NN prediction)) (PP (IN of) (NP (NN lung) (NN lesion) (NN response)))))) (PP (VBN based) (PP (IN on) (NP (NP (JJ radiomic) (NNS features)) (VP (VBN extracted) (PP (IN from) (NP (NP (JJ clinical) (NN CT) (NNS scans)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (JJ non-small) (NML (NN cell) (NN lung)) (NN cancer) (NNS trials)))))))))))) (. .))
(S (NP (DT The) (NN approach)) (VP (VBZ starts) (PP (IN with) (NP (NP (DT the) (NN classification)) (PP (IN of) (NP (NN lung) (NNS lesions))))) (PP (IN from) (NP (NP (NP (DT the) (NN set)) (PP (IN of) (NP (JJ primary)))) (CC and) (NP (NP (JJ metastatic) (NNS lesions)) (PP (IN at) (NP (JJ various) (JJ anatomic) (NNS locations))))))) (. .))
(S (S (VP (VBG Focusing) (PP (IN on) (NP (DT the) (NN lung) (NNS lesions))))) (, ,) (NP (PRP we)) (VP (VBP perform) (NP (JJ automatic) (NN segmentation)) (S (VP (TO to) (VP (VB extract) (NP (PRP$ their) (JJ 3D) (NNS volumes)))))) (. .))
(S (NP (NNP Radiomic) (NNS features)) (VP (VBP are) (ADVP (RB then)) (VP (VBN extracted) (PP (IN from) (NP (NP (DT the) (NN lesion)) (PP (IN on) (NP (NP (DT the) (JJ pre-treatment) (NN scan)) (CC and) (NP (DT the) (JJ first) (NML (NN follow) (HYPH -) (NN up)) (NN scan)))))) (S (VP (TO to) (VP (VB predict) (SBAR (WHNP (WDT which)) (S (NP (NNS lesions)) (VP (MD will) (VP (VB shrink) (S (NP (NP (QP (ADVP (IN at) (RBS least)) (CD 30)) (NN %)) (PP (IN in) (NP (NP (NN diameter)) (PP (IN during) (NP (NP (NN treatment) (PRN (-LRB- -LRB-) (NP (NP (CC either) (NP (NNP Pembrolizumab)) (CC or) (NP (NNS combinations))) (PP (IN of) (NP (NN chemotherapy) (CC and) (NN Pembrolizumab)))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN defined) (PP (IN as) (NP (DT a) (JJ partial) (NN response))) (PP (IN by) (NP (DT the) (NN Response) (NN Evaluation)))))))))))) (NP (NNP Criteria)) (PP (IN In) (NP (NP (NP (JJ Solid) (NNS Tumors)) (-LRB- -LRB-) (NP (NN RECIST)) (-RRB- -RRB-)) (NP (NNS guidelines)))))))))))))) (. .))
(S (S (NP (NP (DT A) (RB 5-fold) (JJ cross) (NN validation)) (PP (IN on) (NP (DT the) (NN training) (NN set)))) (VP (VBD led) (PP (IN to) (NP (NP (DT an) (NN AUC)) (PP (IN of) (NP (QP (CD 0.84) (SYM +) (HYPH /) (SYM -) (CD 0.03)))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN prediction)) (PP (IN on) (NP (DT the) (NN testing) (NN dataset)))) (VP (VBD reached) (NP (NP (NP (NN AUC)) (PP (IN of) (NP (CD 0.73)))) (CONJP (SYM +) (HYPH /) (SYM -)) (NP (NP (CD 0.02)) (PP (IN for) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NML (CD 30) (NN %)) (NN diameter) (NN shrinkage))))))))) (. .))
